Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChowdhury, M.en
dc.contributor.authorMcKenzie, S.en
dc.contributor.authorPearson, C.en
dc.contributor.authorCarr, S.en
dc.contributor.authorPao, C.en
dc.contributor.authorShah, A.en
dc.contributor.authorReus, E.en
dc.contributor.authorEliahoo, J.en
dc.contributor.authorGordon, F.en
dc.contributor.authorBland, H.en
dc.contributor.authorHabibi, P.en
dc.identifier.citationPediatrics, 2013; 131(4):661-669en
dc.description.abstractBackground and Objective: Supportive care remains the mainstay of therapy in bronchiolitis. Earlier studies suggest that helium-oxygen therapy may be beneficial, but evidence is limited. We aimed to compare efficacy of 2 treatment gases, Heliox and Airox (21% oxygen + 79% helium or nitrogen, respectively), on length of hospital treatment for bronchiolitis. Methods: This was a multicenter randomized blinded controlled trial of 319 bronchiolitic infant subjects randomly assigned to either gas; 281 subjects completed the study (140 Heliox, 141 Airox), whose data was analyzed. Treatment was delivered via facemask (nasal cannula, if the facemask intolerant) ± continuous positive airway pressure (CPAP). Severe bronchiolitics received CPAP from the start. Primary end point was length of treatment (LoT) required to alleviate hypoxia and respiratory distress. Secondary end-points were proportion of subjects needing CPAP; CPAP (LoT); and change in respiratory distress score. Results: Analysis by intention to treat (all subjects); median LoT (inter-quartile range, days): Heliox 1.90 (1.08-3.17), Airox 1.87 (1.11-3.34), P = .41. Facemask tolerant subgroup: Heliox 1.46 (0.85-1.95), Airox 2.01 (0.93-2.86), P = .03. Nasal cannula subgroup: Heliox 2.51 (1.21-4.32), Airox 2.81 (1.45-4.78), P = .53. Subgroup started on CPAP: Heliox 1.55 (1.38-2.01), Airox 2.26 (1.84-2.73), P = .02. Proportion of subjects needing CPAP: Heliox 17%, Airox 19%, O.R. 0.87 (0.47-1.60), P = .76. Heliox reduced respiratory distress score after 8 hours (mixed models estimate, -0.1298; P < .001). The effect was greater for facemask compared with nasal cannula (mixed models estimate, 0.093; P = .04). Conclusions: Heliox therapy does not reduce LoT unless given via a tight-fitting facemask or CPAP. Nasal cannula heliox therapy is ineffective.en
dc.description.statementofresponsibilityMina M. Chowdhury, Sheila A. McKenzie, Christopher C. Pearson, Siobhan Carr, Caroline Pao, Arvind R. Shah, Elizabeth Reus, Joseph Eliahoo, Fabiana Gordon, Hubert Bland and Parviz Habibien
dc.publisherAmerican Academy of Pediatricsen
dc.rightsCopyright © 2013 by the American Academy of Pediatrics. All rights reserved.en
dc.subjectRandomized controlled trial; heliox; bronchiolitisen
dc.titleHeliox therapy in bronchiolitis: phase III multicenter double-blind randomized controlled trialen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.